INS and Hypoglycemia: However, a systematic review indicated that the higher lifetime direct costs associated with the pump therapy were partially offset by cost-savings from reduced diabetes-related complications, and that insulin pump therapy was cost-effective for patients with poor glycemic control or problematic hypoglycemia with injections [20].